Furthermore, dysmetabolic adducts including HNE and Nε-(Carboxyethyl)lysine, an advanced glycation end product, are both increased in AD patients’ blood, and their responding IgM levels are decreased with the disease progression [18, 19]. This evidence concerns the gene CD40LG and Alzheimer disease.